Erudio Healtherudio.com
Drug development congress
ESMO Targeted Anticancer Therapies Congress 2027
Feb 22–24, 2027 · Paris, France
Starts in 103 days
- Today · Nov 11
- Feb 22–24Meeting
- Mar 3First reports likely
- Dates
- Feb 22–24, 2027Central European Time (Paris)
- Website
- esmo.org ↗
- On X
- #ESMOTAT27
- Organiser
- European Society for Medical Oncology (ESMO)
- Calendar
- Add to calendar
Trials at ESMO TAT 2027
No trial is placed here yet.
A trial is listed only when at least two public sources, from two different publishers, place its results or presentation at ESMO Targeted Anticancer Therapies Congress 2027; each row says how many did.
Follow #ESMOTAT27 on X ↗ for the first mentions.
What happens next
- Feb 22–24: the meeting; the list fills as clinicians talk about it.
- After: reports on the trials discussed, every statement linked to its source.
Editions
| Edition | Dates | City |
|---|---|---|
| ESMO TAT 2027this page | Feb 22–24, 2027 | Paris |
| ESMO TAT 2026 | Mar 16–18, 2026 | Paris |
| ESMO TAT 2025 | Mar 3–5, 2025 | Paris |
| ESMO TAT 2024 | Feb 26–28, 2024 | Paris |
| ESMO TAT 2023 | Mar 6–8, 2023 | Paris |
| ESMO TAT 2022 | Mar 7–8, 2022 | Virtual |
| ESMO TAT 2021 | Mar 1–2, 2021 | Virtual |
| ESMO TAT 2020 | Cancelled | Paris |
| ESMO TAT 2019 | Feb 25–27, 2019 | Paris |
| ESMO TAT 2018 | Mar 5–7, 2018 | Paris |
Next on the calendar
| Congress | Dates | City |
|---|---|---|
| ELCC 2027 | Mar 17–20 | Munich |
| NCCN 2027 | Mar 19–21 | San Diego |
| SGO 2027 | Mar 19–22 | Phoenix |
How a trial gets on this page
A trial is listed only when at least two public sources, from two different publishers, place its results or presentation at ESMO Targeted Anticancer Therapies Congress 2027; each row says how many did. The list is rebuilt every six hours.Reports
Focused$750Standard$1,250Deep$1,950Pricing
Priced by size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Organised by European Society for Medical Oncology (ESMO); Erudio is not affiliated with it.